The CAR T Convergence: What's at Stake for Big Pharma and Beyond Johnson & Johnson's latest deal with Sail Biomedicines marks a significant escalation in the consolidation of the CAR T therapy market.
This high stakes battle has been brewing among pharmaceutical giants, driven by the rapid expansion of the CAR T therapy market.
CAR T therapies have revolutionized treatment for certain cancers, delivering unprecedented response rates for patients with advanced blood cancers where conventional treatments have failed.